PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives $56.63 Average Target Price from Analysts

Share on StockTwits

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) have been assigned a consensus recommendation of “Buy” from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $56.63.

Several analysts have issued reports on PTCT shares. Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $58.00 price objective on shares of PTC Therapeutics in a research report on Thursday. Credit Suisse Group reaffirmed a “buy” rating and set a $54.00 price objective on shares of PTC Therapeutics in a research report on Thursday, October 31st. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, October 30th. Finally, SunTrust Banks began coverage on PTC Therapeutics in a research report on Tuesday, November 12th. They set a “buy” rating and a $78.00 target price on the stock.

In other news, CEO Stuart Walter Peltz sold 22,463 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $49.43, for a total value of $1,110,346.09. Corporate insiders own 7.00% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Quantamental Technologies LLC acquired a new position in shares of PTC Therapeutics during the second quarter worth approximately $49,000. Meeder Asset Management Inc. raised its position in PTC Therapeutics by 2,347.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 1,738 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,667 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in PTC Therapeutics by 15.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,596 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 474 shares during the period. Tower Research Capital LLC TRC acquired a new stake in shares of PTC Therapeutics during the 3rd quarter worth approximately $130,000. Finally, Aperio Group LLC bought a new position in PTC Therapeutics in the second quarter valued at approximately $168,000. Hedge funds and other institutional investors own 99.31% of the company’s stock.

Shares of PTC Therapeutics stock opened at $49.20 on Friday. The company’s fifty day simple moving average is $42.36 and its 200-day simple moving average is $42.01. The company has a market cap of $3.03 billion, a price-to-earnings ratio of -26.74 and a beta of 1.90. The company has a current ratio of 4.40, a quick ratio of 4.30 and a debt-to-equity ratio of 0.44. PTC Therapeutics has a 1 year low of $27.53 and a 1 year high of $50.96.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.15). PTC Therapeutics had a negative return on equity of 31.92% and a negative net margin of 74.86%. The company had revenue of $71.40 million for the quarter, compared to the consensus estimate of $72.03 million. During the same period last year, the firm posted ($1.06) EPS. The company’s revenue was up 33.2% compared to the same quarter last year. As a group, research analysts forecast that PTC Therapeutics will post -3.1 earnings per share for the current fiscal year.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients.

See Also: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.